

# **GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED**

**UNAUDITED FINANCIAL RESULTS FOR THE  
QUARTER ENDED JUNE 30, 2014**



# GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

PART I						(Rs. in Lakhs)
Statement of Standalone Unaudited Results for the Quarter ended 30/06/2014						
PARTICULARS (Refer Notes Below)		3 Months Ended 30/06/2014	Preceding 3 Months Ended 31/03/2014	Corresponding 3 Months Ended 30/06/2013 in the previous year	Previous year (15 Months) ended 31/03/2014	
		UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Income from Operations (a) Net Sales / Income from Operations (Net of Excise Duty) (b) Other Operating Income	9,21,55 44,42	10,79,09 40,73	8,52,92 37,38	46,82,92 1,85,66	
2	Total Income from operations (Net)	9,65,97	11,19,82	8,90,30	48,68,58	
	Expenses					
	(a) Cost of material consumed	3,46,95	3,34,52	2,81,10	15,24,13	
	(b) Purchase of stock-in-Trade	39,03	48,22	35,70	2,06,54	
	(c) Change of inventories of finished goods, work-in-progress and stock-in-trade	(34,05)	35,07	(18,17)	8,91	
	(d) Employee benefits expense	1,05,43	1,00,32	1,04,41	4,70,05	
	(e) Advertising & Promotion	1,41,40	1,85,75	1,37,56	8,10,62	
	(f) Depreciation and Amortisation expense	11,91	16,87	12,20	62,55	
	(g) Other Expenses	2,02,57	1,85,93	1,93,66	9,75,55	
	Total Expenses	8,13,24	9,06,68	7,46,46	40,58,35	
3	Profit from operations before other income, finance costs and exceptional Items (1-2)	1,52,73	2,13,14	1,43,84	8,10,23	
4	Other income	45,76	48,00	38,53	2,06,91	
5	Profit from Ordinary activities before finance costs and exceptional Items (3+4)	1,98,49	2,61,14	1,82,37	10,17,14	
6	Finance costs	19	17	16	1,05	
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	1,98,30	2,60,97	1,82,21	10,16,09	
8	Exceptional items	-	-	-	-	
9	Profit from ordinary activities before tax (7+8)	1,98,30	2,60,97	1,82,21	10,16,09	
10	Tax expense	68,18	89,26	62,25	3,41,33	
11	Net Profit from ordinary activities after tax (9-10)	1,30,12	1,71,71	1,19,96	6,74,76	
12	Extraordinary items (net of tax expense)	-	-	-	-	
13	Net Profit for the period (11-12)	1,30,12	1,71,71	1,19,96	6,74,76	
14	Paid Up equity share capital (Face Value of Equity Shares)	42,06 10	42,06 10	42,06 10	42,06 10	
15	Reserve excluding Revaluation Reserve as per Balance Sheet of the previous accounting year				17,70,79	
16. i	Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic and (b) Diluted	30.94	40.83	28.52	160.44	
16. ii	Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised): (a) Basic and (b) Diluted	30.94	40.83	28.52	160.44	



**Part II**

**Select Information for the Quarter ended 30/06/2014**

<b>A. PARTICULARS OF SHAREHOLDING</b>					
		<b>3 Months Ended 30/06/2014</b>	<b>Preceding 3 Months Ended 31/03/2014</b>	<b>Corresponding 3 Months Ended 30/06/2013 in the previous year</b>	<b>Previous year (15 Months) ended 31/03/2014</b>
<b>1. Public Shareholding</b>					
- Number of Shares		1,15,83,546	1,15,83,546	1,15,83,546	1,15,83,546
- Percentage of Shareholding		27.54	27.54	27.54	27.54
<b>2. Promoters and Promoter Group Shareholding</b>					
<b>a) Pledged/ Encumbered</b>					
- Number of shares		-	-	-	-
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)		-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)		-	-	-	-
<b>b) Non-encumbered</b>					
- Number of shares		3,04,71,992	3,04,71,992	3,04,71,992	3,04,71,992
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter Group)		100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the Company)		72.46	72.46	72.46	72.46
<b>Particulars</b>		<b>3 months ended 30th June 14</b>			

**B. INVESTOR COMPLAINTS**

Pending at the beginning of the quarter  
 Received during the quarter  
 Disposed of during the quarter  
 Remaining unresolved at the end of the quarter

NIL  
 68  
 68  
 NIL



GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED  
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2014

NOTES

- 1) The Company's nutritional business is India focused and in a single business and geographical segment. Accordingly segment information is not applicable.
- 2) The Company received 68 investor complaints during the quarter ended June 30, 2014 which were duly resolved by the end of the quarter. There were no investor complaints pending at the beginning and at the end of the quarter.
- 3) The unaudited financial results for the quarter ended June 30, 2014 have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at its meeting held on August 6, 2014. The Limited Review for the unaudited financial results for the quarter ended June 30, 2014, as required under Clause 41 of the Listing Agreement has been completed by the statutory auditors
- 4) Figures for the previous period have been regrouped/reclassified wherever necessary, to conform to the current period's classification.

REGD. OFFICE: PATIALA ROAD, NABHA 147201 (PUNJAB).  
HEAD OFFICE: DLF PLAZA TOWER, DLF CITY PHASE I,  
GURGAON - 122002, HARYANA.

NABHA  
August 6, 2014

ON BEHALF OF THE BOARD


*Kubair Ahmed*  
ZUBAIR AHMED  
MANAGING DIRECTOR



The Board of Directors  
GlaxoSmithKline Consumer Healthcare Limited  
DLF Plaza Tower  
DLF City Phase-I  
Gurgaon 122002  
Haryana, India

1. We have reviewed the results of GlaxoSmithKline Consumer Healthcare Limited (the "Company") for the quarter ended June 30, 2014 which are included in the accompanying "Statement of Standalone Unaudited Results for the Quarter ended 30/06/2014" (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the Management but have neither been reviewed nor been audited by us. The Statement has been prepared by the Company pursuant to Clause 41 of the Listing Agreement with the Stock Exchanges in India, which has been initialled by us for identification purposes. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. We have only traced the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' in the Statement from the disclosures made by the Management and are, therefore, not expressing a review opinion thereon.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 read with the General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse  
Firm Registration Number: 301112E  
Chartered Accountants



Usha Rajeev  
Partner  
Membership Number : 087191

Place : Gurgaon  
Date : August 6, 2014